All Topics
Find news about people
Find news on alumni of any org
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


Change Feed
... over by private equity firms Bain Capital and Cinven last September, and Sanofi recently sold off Zentiva to Advent for €1.9 billion. Italy's rare disease ...
... purpura (aTTP), a rare blood-clotting disorder. Cablivi was developed by Ablynx, a Sanofi Company. The European Commission will review the CHMP recommendation and a final ...
... Global biopharmaceutical company Sanofi has announced plans to establish a global research and development (R&D) operations ...
... Sanofi has completed the strategic integration of its infectious disease unit, including most ...
... PARIS - Sanofi and Advent International ('Advent') have finished negotiations for the acquisition of Zentiva, ...
... of July 16, coming off a nearly 12-year stint at Genzyme and Sanofi. Most recently, he was the French Big Pharma's senior VP, global head ...
... on the heels of completing its €3.9 billion ($4.5 billion) Ablynx acquisition, Sanofi has won a European recommendation for the first product out of that ...
Subscribe now for full coverage on Sanofi
Start My Free Trial